Pathogenic Neisseria Bind the Complement Protein CFHR5 via Outer Membrane Porins

Wearn-Xin Yee, Christoph M. Tang, Hayley Lavender

Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom

ABSTRACT Neisseria meningitidis and Neisseria gonorrhoeae are important human pathogens that have evolved to bind the major negative regulator of the complement system, complement factor H (CFH). However, little is known about the interaction of pathogens with CFH-related proteins (CFHRs) which are structurally similar to CFH but lack the main complement regulatory domains found in CFH. Insights into the role of CFHRs have been hampered by a lack of specific reagents. We generated a panel of CFHR-specific monoclonal antibodies and demonstrated that CFHR5 was bound by both pathogenic Neisseria spp. We showed that CFHR5 bound to PorB expressed by both pathogens in the presence of sialylated lipopolysaccharide and enhanced complement activation on the surface of N. gonorrhoeae. Our study furthered our understanding of the interactions of CFHRs with bacterial pathogens and revealed that CFHR5 bound the meningococcus and gonococcus via similar mechanisms.

KEYWORDS Neisseria gonorrhoeae, Neisseria meningitidis, complement, CFH, CFHR

The complement system is a key component of the innate immune system and is critical for the recognition and elimination of invading microorganisms. Complement can be activated by three main pathways, the classical, lectin, and alternative pathway (AP) (reviewed in reference (1)), with all the pathways generating a C3 convertase which cleaves C3 into C3a and C3b. C3b then binds to the activating surface leading to opsonization with or without lysis through the terminal complement pathway (2). As C3b binds nonspecifically to both host and pathogen molecules, complement activation must be tightly regulated to prevent host cell damage (3). Complement factor H (CFH) is the major negative regulator of the AP and inhibits complement activity by preventing the formation of the AP C3 convertase or accelerating its decay, and by acting as a cofactor for C3b cleavage mediated by factor I. CFH consists of 20 Complement control protein modules (CCPs) which each consist of approximately 60 amino acids (4, 5). The four N-terminal CCP domains of CFH (CFH[1-4]) possess complement regulatory activity, while other domains, such as CFH[7] and CFH[19-20], enable interaction with ligands such as glycosaminoglycans, sialic acid found on host cells and the C3 activation fragment, C3b (6, 7).

Aside from CFH, five complement factor H-related proteins (CFHR1-5) are also composed of CCPs and share significant structural and sequence similarities with CFH. Of note, all CFHRs lack CCPs related to the complement regulatory domains of CFH[1-4] (Fig. 1A). However, CFHRs 1(4,5), 2(3,4), and 5(8,9) share >40% amino acid similarity with CFH[19,20] (7). The homology of the CFHRs to the surface recognition domains of CFH[19,20] enables these proteins to bind similar or the same molecules on surfaces. However, as the CFHRs lack CCPs required for complement regulatory activity (CFH[1-4]), there is accumulating evidence that CFHRs can modulate complement activity (7, 8), with genetic studies indicating CFHRs’ importance in disease. For example, the loss of CFHR3-CFHR1 or CFHR1-CFHR4, or the expression of CFHR1 variants, including CFHR-CFH hybrids can result in atypical haemolytic Uraemic syndrome (aHUS) (reviewed in reference (9)). Several CFHRs, including

Editor Denise Monack, Stanford University
Copyright © 2022 Yee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Address correspondence to Hayley Lavender, hayley.lavender@path.ox.ac.uk.
The authors declare no conflict of interest.
Received 29 August 2022
Accepted 8 September 2022
Published 4 October 2022
FIG 1 Characterization of anti-CFHR MAbs. (A) Complement control protein (CCP) domains of CFH and CFHRs 1 to 5 are shown with CCPs aligned with domains of CFH that share sequence homology. CFH CCPs that bind Neisseria spp. are indicated with (Continued on next page)
CFHR2, 3 and 5 can antagonize the regulatory activity of CFH by competing for binding sites on activating surfaces (7). CFHR5 can also activate complement by recruiting other complement proteins such as properdin into a heteromeric complex (10, 11). Despite this, there are still relatively few studies on CFHRs, partly because of the paucity of reagents that can discriminate between them.

Many bacterial pathogens have evolved to recruit CFH via CFH(6,7) or instead of and CFH(19,20) to subvert the complement system (12). However, little is known about the interactions between bacteria and CFHRs. Due to the extensive sequence identity of CFHR1(3-5) with CFH(18-20) (Fig. 1A), CFHR1 can bind to several bacteria, including *Borrelia*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Neisseria gonorrhoeae* (13–16). *Borrelia* also binds CFHRs 2 and 5 (13). Furthermore, CFHR3 can compete with CFH for binding to the surface of *Neisseria meningitidis* (17), highlighting the potential role of CFHRs during bacterial infections.

*N. meningitidis* and *N. gonorrhoeae* are closely related human-adapted pathogens which recruit CFH to subvert complement activation. *N. meningitidis* is a leading cause of sepsis and bacterial meningitis, whereas *N. gonorrhoeae* is responsible for the sexually transmitted infection, gonorrhoea (18). *N. meningitidis* recruits CFH via a surface lipoprotein, factor H binding protein (fHbp) (19), which binds to CFH(6,7) with nanomolar affinity (17). In the absence of fHbp and capsule, meningococcal NspA and PorB can associate with CFH (20, 21). Gonococcal fHbp is not surface-expressed and does not bind CFH (22). Instead, *N. gonorrhoeae* binds CFH(18-20) via PorB (23), an integral outer membrane porin with eight surface exposed loops (L1-L8). Gonococci express one class of PorB, P.IA, or P.IB, which share >80% nucleotide sequence identity (24, 25). Different loops of P.IA and P.IB are responsible for CFH binding, with L5 of P.IA and L3-7 of P.IB involved in binding CFH (26, 27). Furthermore, the addition of sialic acid to bacterial lipopolysaccharide (LPS) by the α-2,3-sialyltransferase, Lst (28), is required for CFH binding to gonococcal P.IB but not P.IA (26, 27). Little is known about CFHR binding by pathogenic *Neisseria*, although meningococcal fHbp binds both CFHR3 and CFH (17). However, nothing is known about the interactions of CFHR2, 4, and 5 with pathogenic *Neisseria*.

Here, we describe the generation and characterization of monoclonal antibodies (MAbs) that specifically bind to CFHR2, 4, and 5. Using these MAbs, we revealed that CFHR5, but not CFHR2 or 4, bound to PorB from both *N. meningitidis* and *N. gonorrhoeae* only when the LPS was sialylated. We identified the loops of *N. gonorrhoeae* PorB that were responsible for interactions with CFHR5 and showed that there were similarities with the regions of PorB that engaged CFH. Furthermore, we demonstrated that surface-bound CFHR5 enhanced *N. gonorrhoeae* susceptibility to human complement.

(Work has been previously presented at American Society for Microbiology Microbe 2020 conference by W.X.Y. Title: CFHR5 binds to *Neisseria gonorrhoeae*. Authors: W.X.Y., H.L. and C.M.T.)

### RESULTS

**Generation of specific MAbs against CFHRs.** Understanding the function of CFHRs has been hampered by the lack of specific reagents, with many antibodies against CFH and CFHRs cross-reacting with other family members because they share considerable amino acid identity (Fig. 1A). We previously isolated a specific anti-CFHR3 MAb, HSL-1 (17), while OX-24 is a MAb which specifically recognizes CFH(29). However, few specific reagents have been generated against other CFHRs (30–32). We generated anti-CFHR 2, 4, and 5 MAbs by standard hybridoma technology (17) using recombinant CFHR2(3-4), CFHR5(8,9), or a synthetic peptide from CFHR4 as antigens. Candidate anti-CFHR2 and anti-CFHR5 MAbs were screened...
by an enzyme-linked immunosorbent assay (ELISA) for cross-reactivity to CFH and other CFHRs using the two C-terminal CCPs of CFH and CFHRs 1 to 5. The results identified specific MAbs against CFHR2 and CFHR5, designated HSL-2 and HSL-5, respectively (Fig. 1B and C). A MAb against CFHR4, designated HSL-4, recognized the immunizing CFHR4 peptide by an ELISA (Fig. 1D). Furthermore, the specificity of MAbs HSL-2, -5, and -4 was assessed by Western blotting of normal human serum (NHS) to demonstrate the molecular weight of proteins detected, identify cross-reactivity with other serum proteins, and determine if MAbs recognize known posttranslational modifications, e.g., glycosylation of CFHRs (8) (Fig. 1E to G).

Both HSL-2 and HSL-5 recognized two bands in NHS consistent with the molecular masses of differentially glycosylated forms of CFHR2 and CFHR5 that have previously been described (8) (Fig. 1E and F). CFHR4 encodes two splice variants, CFHR4A, and CFHR4B, with approximate molecular masses of 86 and 42 kDa, respectively (33), both of which were recognized by HSL-4 (Fig. 1A and G). Importantly, the three MAbs specifically recognized the immunizing CFHR and no other protein in NHS by ELISA and Western blot (Fig. 1B to G).

**FIG 2** *N. meningitidis* bound CFHR5 independent of fHbp. Flow cytometry was used to detect the binding of CFH and CFHRs to *N. meningitidis* H44/76 and H44/76ΔfHbp. CFH (blue), CFHR2 (orange), CFHR3 (green), CFHR4 (purple) and CFHR5 (red) in NHS using specific MAbs. Bacteria incubated with no primary antibody (gray trace) were used as a control. (A) Representative histograms and (B) comparison of geometric mean fluorescence intensity and S.D. of independent assays (n ≥ 3) are as indicated. Unpaired t tests were used to compare the fluorescence intensity of CFHR and CFH MAb binding between wild-type *N. meningitidis* H44/76 and H44/76ΔfHbp. ns, *P* ≥ 0.05; *, *P* ≤ 0.05; **, *P* ≤ 0.01.

by an enzyme-linked immunosorbent assay (ELISA) for cross-reactivity to CFH and other CFHRs using the two C-terminal CCPs of CFH and CFHRs 1 to 5. The results identified specific MAbs against CFHR2 and CFHR5, designated HSL-2 and HSL-5, respectively (Fig. 1B and C). A MAb against CFHR4, designated HSL-4, recognized the immunizing CFHR4 peptide by an ELISA (Fig. 1D). Furthermore, the specificity of MAbs HSL-2, -5, and -4 was assessed by Western blotting of normal human serum (NHS) to demonstrate the molecular weight of proteins detected, identify cross-reactivity with other serum proteins, and determine if MAbs recognize known posttranslational modifications, e.g., glycosylation of CFHRs (8) (Fig. 1E to G).

Both HSL-2 and HSL-5 recognized two bands in NHS consistent with the molecular masses of differentially glycosylated forms of CFHR2 and CFHR5 that have previously been described (8) (Fig. 1E and F). CFHR4 encodes two splice variants, CFHR4A, and CFHR4B, with approximate molecular masses of 86 and 42 kDa, respectively (33), both of which were recognized by HSL-4 (Fig. 1A and G). Importantly, the three MAbs specifically recognized the immunizing CFHR and no other protein in NHS by ELISA and Western blot (Fig. 1B to G).

**CFHR5 bound to PorB from *N. meningitidis*.** With these MAbs, we next determined whether CFHR2, 4, or 5 bind to *N. meningitidis*. Because both CFH and CFHR3 bind *N. meningitidis* via fHbp (17, 19), we wanted to establish if any potential interaction was dependent on fHbp. Flow cytometry demonstrated that *N. meningitidis* bound CFH and CFHR3 in an fHbp-dependent manner as previously (17) (Fig. 2, binding of CFH and CFHR3 to *N. meningitidis* H44/76ΔfHbp *P* = 0.0136 and 0.0012, respectively, compared with wild-type bacteria, unpaired two-tailed *t* test). In contrast, no significant binding of CFHR2 or CFHR4 was detected to *N. meningitidis* in the presence/absence of fHbp (Fig. 2; *P* = 0.3473 and *P* = 0.0935 using an unpaired two-tailed *t* test). However, we found that CFHR5 bound to *N. meningitidis* H44/76 independent of fHbp (wild-type strain versus H44/76ΔfHbp, *P* = 0.4799, unpaired two-tailed *t* test, Fig. 2).
N. gonorrhoeae binds CFH to a region of external loop 5 of Por.IB. N. meningitidis expresses two outer membrane porins, PorA and PorB which share 40 to 50% and 60 to 70% amino acid identity, respectively, with gonococcal PorB (34, 35). Furthermore, CFHR5(8,9) shares 40 to 70% similarity with CFH(19,20) (7), the latter bound to meningococcal PorB (20). Therefore, we hypothesized that CFHR5 might bind to either meningococcal PorA or PorB. We assessed CFHR5 binding to isogenic DporA or DporB mutants using NHS a st h es o u r c eo fC F H R 5 .O fn o t e ,t h e D porB mutant exhibited significantly reduced CFHR5 binding compared to the wild-type strain (P = 0.0485, one-way analysis of variance [ANOVA]; Fig. 3A), indicating that PorB is a receptor for CFHR5 on the meningococcus. There was a nonsignificant increase in CFHR5 binding to H44/76 DporA (P = 0.4011, one-way ANOVA), consistent with the nonsignificant increase in PorB expression by the DporA strain (P = 0.5292, one-way ANOVA; Fig. S1 in Supplemental File 1).

Because CFH binding to gonococcal PorB can be modulated by the addition of sialic acid to LPS (26), we next determined the influence of structures containing sialic acid on CFHR5 binding to N. meningitidis MC58, which expresses a polysialic acid capsule and endogenously sialylates its LPS (36). We examined CFHR5 binding to strains that were defective for LPS sialylation (MC58Δlst), capsule biosynthesis (MC58Δcsb), or both (MC58ΔcsC, which is unable to synthesize sialic acid (37)). While there was no significant difference in CFHR5 binding to MC58Δcsb compared with the wild-type strain (P = 0.0792, one-way ANOVA), there was no detectable CFHR5 binding to MC58ΔcsC or MC58Δlst (Fig. 3B; P = 0.0019 and P = 0.0037, respectively, compared to wild-type, one-way ANOVA). Therefore, CFHR5 binding to N. meningitidis PorB is dependent on LPS sialylation.

N. meningitidis expresses one of two classes of PorB, PorB2 or PorB3, encoded by different alleles at the porB locus (34). Therefore, we examined whether PorB belonging to different classes exhibited differences in CFHR5 binding. Flow cytometry of CFHR5 binding to a range of isolates indicated that both classes of meningococcal PorB mediated CFHR5 binding (Fig. 3C).

**FIG 3** CFHR5 bound to N. meningitidis PorB. (A) Flow cytometry analysis demonstrates the binding of CFHR5 to wild-type N. meningitidis H44/76 (solid line), H44/76ΔporA (dashed line), and H44/76ΔporB (dotted line); representative histograms are shown. (B) Flow cytometry analysis of CFHR5 binding to wild-type N. meningitidis MC58 (black), MC58ΔcsC (dark red), MC58Δcsb (red), and MC58Δlst (light red); representative histograms are shown. Comparison of geometric mean fluorescence intensity and S.D. of independent assays (n ≥ 3) are indicated. Unpaired t test and one-way ANOVA method of multiple comparisons were used to compare the fluorescence intensity of CFHR5 binding and PorA/PorB levels versus control samples lacking the primary antibody (gray); ns, P ≥ 0.05; *, P ≤ 0.05; **, P ≤ 0.01. (C) CFHR5 bound N. meningitidis expressing class 2 and class 3 PorB by flow cytometry.
N. gonorrhoeae bound CFHRs. We next examined whether N. gonorrhoeae bound to CFHRs 2 to 5. We assessed CFHR binding to N. gonorrhoeae FA1090 grown with or without cytidine-5′-monophosphate-N-acetylneuraminic acid (CMP-NANA) as N. gonorrhoeae only sialylates its LPS when provided with an exogenous source of sialic acid. CFHRs/CFH binding was detected by flow cytometry using relevant MAbs. The results demonstrated that N. gonorrhoeae bound CFH and CFHR5, but not CFHR2, 3, or 4 (Fig. 4A) under the conditions tested. The binding of both CFH and CFHR5 was dependent on the presence of sialic acid during growth (P = 0.0288 and P = 0.0281, respectively, unpaired two-tailed t test; Fig. 4B). These findings were confirmed using purified CFH and recombinant CFHR5 (P $\leq$ 0.0001 and P = 0.0032, respectively, compared to bacteria grown without CMP-NANA, using unpaired two-tailed t test; Fig. S2 in Supplemental File 1), which demonstrated that no binding of either protein in the absence of LPS sialylation.

Loops 1 and 6 of gonococcal PorB showed differential binding of CFH and CFHR5. We hypothesized that gonococcal PorB might also be the target for CFHR5 binding, similar to the meningococcus. N. gonorrhoeae expresses one of two classes of PorB, P.IB, and P.IA (34, 38). FA1090 expresses P.IB PorB. PorB is essential in N. gonorrhoeae (39) therefore, we examined CFHR5 binding to strains with modified P.IB surface loops that have previously been used to characterize CFH binding (Table 1 and Fig. 5A) (26). We also substituted leucine at position 253 with methionine in loop 6 as this residue is involved in binding the negative complement regulator C4bp (26). Strains with modified PorB loops were designated Lnxxx, with Ln representing the PorB loop number, and xxx representing the amino acid(s) substituted (—) or deleted (Δ) (Table 1 and Fig. 5A). Modification of PorB loops did not affect PorB expression or growth of bacteria (Fig. S3 in Supplemental File 1). Bacteria were incubated with NHS as the source of CFH and CFHR5 which were detected with MAbs OX-24 or HSL-5, respectively. Strains L3116-121--Ala, L4171-176, L5203-224, and L7290-295--Ala exhibited loss of
both CFH and CFHR5 binding ($P \leq 0.0001$ compared to wild-type FA1090, one-way ANOVA, Fig. 5C and D). Of note, while L6254-259 \textit{Ala} showed a significant decrease in CFH binding compared with wild-type bacteria, CFHR5 binding was not detected ($P \leq 0.0001$, one-way ANOVA). In contrast, there was a significant decrease in CFH binding to strain L143-48 \textit{Ala} ($P = 0.0019$, one-way ANOVA), while CFHR5 binding was unchanged. Interestingly, strain L6L253M showed a significant decrease in CFHR5 binding ($P = 0.0154$ using one-way ANOVA), while CFH binding was unaffected. L283-88 \textit{Ala} and L3134-139 \textit{Ala} exhibited no change in CFH ($P = 0.3931$ and $P = 0.3577$, respectively, one-way ANOVA) or CFHR5 binding compared with the wild-type strain ($P = 0.3301$ and $P = 0.9997$, respectively, one-way ANOVA) (Fig. 5C and D). Overall, the results indicated that, while several PorB modifications had similar effects on CFHR5 and CFH binding, modification of L1 affected the binding of CFH more than CFHR5, while modification of L6 reduced CFHR5 binding disproportionately compared with CFH.

**CFHR5 bound a range of gonococcal isolates.** Next, we further interrogated which PorB loops are important for CFHR5 and CFH binding using clinical isolates with amino acid substitutions in PorB compared to FA1090 P.1B (Fig. 6A). Whole-genome sequences were interrogated using the PubMLST \textit{Neisseria} BigSdb database (https://pubmlst.org/organisms/neisseria-spp) (40). The results demonstrated that \textit{N. gonorrhoeae} NG102, which has numerous substitutions in loops 1, 3, and 6 and an insertion of two amino acids in loop 5, did not bind CFHR5 (Fig. 6B and C) and exhibited reduced CFH binding (Fig. 6D; $P = 0.0003$, one-way ANOVA). Analysis of strain 65737, which has amino acid substitutions in loops 1, 3, and 6, also showed a reduction of CFHR5 and CFH binding compared with FA1090 (Fig. 6B to D; $P = 0.0017$ and $P = 0.0039$, respectively, one-way ANOVA). The role of loop 5 was examined using isolates NG102 and

### TABLE 1 \textit{Neisseria} species isolates

| Strain            | Year | Country | cc | ST        | Strain type       | Reference |
|-------------------|------|---------|----|-----------|-------------------|-----------|
| \textit{Neisseria meningitidis} |      |         |    |           |                   |           |
| H44/76            | 1976 | Norway  | 32 | 32        | B:15:P1.7,16      | 53        |
| H44/76\textit{ΔPorB} |       |         |    |           |                   | 22        |
| H44/76\textit{ΔPorA} |       |         |    |           |                   | 54        |
| H44/76\textit{ΔSbp} |       |         |    |           |                   | This study|
| MC58              | 1985 | UK      | 32 | 74        | B:15:P1.7,16b     | 55        |
| MC58\textit{ΔcssC} |       |         |    |           |                   | 37        |
| MC58\textit{Δcsb} |       |         |    |           |                   | 37        |
| MC58\textit{ΔSt} |       |         |    |           |                   | 37        |
| M1239             | 1994 | USA     | 41 | 44        | B:14:P1.23,14     | 56        |
| BZ10              | 1967 | Netherlands | 8  | 8         | B: P1.5-1,2-2     | 57        |
| Fam18             | 1983 | USA     | 11 | 11        | C2a:P1.5,2        | 58        |
| Z2491             | 1983 | Africa  | 4  | 4         | A: P1.7,13-1      | 59        |
| M07.0240684       | 2007 | UK      | 23 |           |                   | 60        |
| \textit{Neisseria gonorrhoeae} |      |         |    |           |                   |           |
| FA1090 G4         | 1980 | USA     |    |           |                   | 61        |
| L4 \textit{L1-48-48} |   | -       | -  |           |                   | 26        |
| L4 \textit{L3-88-88} |   | -       | -  |           |                   | 26        |
| L4 \textit{L1-121-121} |   | -       | -  |           |                   | 26        |
| L4 \textit{L3-134-139} |   | -       | -  |           |                   | 26        |
| L4 \textit{L4-171-176} |   | -       | -  |           |                   | 26        |
| L5 \textit{L5-203-224} |   | -       | -  |           |                   | 26        |
| L6 \textit{L6-253M} |   | -       | -  |           |                   | 26        |
| L6 \textit{L6-254-259} |   | -       | -  |           |                   | 26        |
| L7 \textit{L7-295-259} |   | -       | -  |           |                   | 26        |
| NG102             | 2012 | UK      |    |           |                   | 22        |
| NG104             | 2012 | UK      |    |           |                   | 22        |
| NG118             | 2012 | UK      |    |           |                   | 22        |
| 65737             | 2014 | Kenya   |    |           |                   | 62        |
| 60755             | 2013 | Kenya   |    |           |                   | 62        |
| 55496             | 2012 | Kenya   |    |           |                   | 62        |

\textit{a}, the information is not available due to it being a strain generated in the study.
NG106 which have one or two amino acid substitutions in this loop compared with *N. gonorrhoeae* FA1090. Both these strains bind CFHR5 to a similar extent but had significantly reduced CFH binding ($P = 0.0155$ and $P = 0.0021$ versus FA1090, respectively, one-way ANOVA) (Fig. 6B to D). This suggested that specific residues on loop 5 may exhibit differential binding to CFH and CFHR5. Of note, two clinical isolates expressing PorB and P.IA did not bind CFHR5 (Fig. S4 in Supplemental File 1).

**Binding of CFHR5 to *N. gonorrhoeae* enhanced complement activation.** To examine the biological consequences of *N. gonorrhoeae* binding CFHR5, strain FA1090 was preincubated with 4 μM exogenous recombinant CFHR5 before the addition of antibody-depleted human complement (hComplement). Preincubation of sialylated FA1090 with CFHR5 resulted in significantly reduced survival of FA1090 (two-way ANOVA $P = 0.0005$) compared to bacteria with no CFHR5 (Fig. 7A). In contrast, CFHR5 did not affect bacterial survival when LPS was not sialylated (two-way ANOVA $P = 0.9995$) (Fig. 7A). Furthermore, the addition of CFHR5 did not affect bacterial survival of
sialylated or unsialylated FA1090 in the presence of Heat-inactivated (HI)-hComplement (two-way ANOVA, P = 0.9864 and >0.9999, respectively) (Fig. 7B). Of note, unsialylated FA1090 was significantly more susceptible to complement-mediated lysis than sialylated bacteria as expected (two-way ANOVA, P = 0.0009) (Fig. 7A).

**DISCUSSION**

Complement is a crucial aspect of the innate immune system and defense against invading pathogens. This is highlighted by the susceptibility of individuals with complement defects to infectious diseases, and the array of complement evasion mechanisms exhibited by pathogenic bacteria (reviewed in reference (2)). Recruitment of CFH, the major negative regulator of the AP, is exploited by pathogenic *Neisseria* to subvert complement-mediated attack. However, unlike CFH, little is known about
CFHRs binding to bacterial pathogens, with the study of CFHRs hampered by the lack of specific reagents, although recently MAbs that recognize CFHR2, 4, and 5 have been described and used to measure the respective CFHR levels in serum (30, 31, 41). Here, we generated MAbs which specifically recognize CFHR2, 4, and 5 and utilized them to detect the binding of these proteins to *N. meningitidis* and *N. gonorrhoeae*. 

Even though CFH and the CFHRs share high sequence and structural similarity, we successfully generated specific MAbs using recombinant CFHR2(3,4), CFHR5(8,9), and a linear peptide of CFHR4(3) which recognize different glycosylated forms of these proteins in serum. This indicates that the MAbs recognize epitopes distinct from posttranslational modification sites (8). Furthermore, our anti-CFHR4 MAb recognizes both splice variants of CFHR4 in NHS, contrary to previous studies which suggest that only a single variant is present in serum. This discrepancy could be explained by the variable circulating levels of CFHR4 (31).

While there are limited data on the function of CFHRs, genetic studies have highlighted their contribution to complement-mediated diseases and in particular meningococcal infection (42–44). Therefore, these MAbs will help assess CFHR levels during health and disease, and the interaction of CFHRs with pathogenic microbes as exemplified here.

Here, we used serum-derived CFH and CFHRs 2 to 5 to detect binding to *N. meningitidis* and *N. gonorrhoeae*. Even though CFH and the CFHRs share high sequence and structural similarity, we successfully generated specific MAbs using recombinant CFHR2(3,4), CFHR5(8,9), and a linear peptide of CFHR4(3), which recognize different glycosylated forms of these proteins in serum. This indicates that the MAbs recognize epitopes distinct from posttranslational modification sites (8). Furthermore, our anti-CFHR4 MAb recognizes both splice variants of CFHR4 in NHS, contrary to previous studies which suggest that only a single variant is present in serum. This discrepancy could be explained by the variable circulating levels of CFHR4 (31). While there are limited data on the function of CFHRs, genetic studies have highlighted their contribution to complement-mediated diseases and in particular meningococcal infection (42–44). Therefore, these MAbs will help assess CFHR levels during health and disease, and the interaction of CFHRs with pathogenic microbes as exemplified here.

Here, we used serum-derived CFH and CFHRs 2 to 5 to detect binding to *N. meningitidis* and *N. gonorrhoeae*. This ensures that the proteins are postranslationally modified and correctly folded. As previously found (17, 19), we demonstrated that CFHR3 was bound to *N. meningitidis* in an fhbp-dependent manner. Furthermore, the minor residual CFH binding to the Δfhbp mutant can be attributed to its interaction with NspA and PorB2, as previously described (21, 45). The gonococcal homolog of fhbp is not surface exposed (22), explaining why we detected no CFHR3 binding to *N. gonorrhoeae*. *N. gonorrhoeae* has been shown to bind purified CFHR1 (16). However, we could not confirm this using serum CFHR1. Of the other CFHRs, we only detected CFHR5 binding to the meningococcus and the gonococcus. However, we could not exclude the possibility that pathogenic *Neisseria* also bound CFHRs 2 and 4. Serum levels of CFHR4, CFHR2, and heterodimers of CFHR1 and 2 are relatively low (2.55 ± 1.46, 0.7 ± 0.4, and 5.8 ± 2.4 μg/mL, respectively) (30, 32) which might limit their detection in our assays (30, 32, 41). Therefore, the ability of *N. gonorrhoeae* and *N. meningitidis* to bind CFHR2 and 4 should be investigated using purified proteins.
PorB is an outer membrane porin that forms a 16-stranded β-barrel with eight outer membrane loops and assembles into trimers (46, 47). Both N. meningitidis and N. gonorrhoeae strains express one of two mutually exclusive PorB classes (PorB2 and PorB3, and P.IA and P.IB, respectively) (34). In N. meningitidis, isolates expressing either class 2 or 3 PorB bind CFHR5. Therefore, CFHR5 might bind to the nonvariable, surface-exposed L2, 3, 4, or 8. In contrast, CFH has been hypothesized to bind to variable loops 1, 5, 6, and 7 (20). In N. gonorrhoeae, both P.IA and P.IB share 65 to 80% amino acid homology (48), with main differences in the surface exposed loops, especially in loop 5. Of note, P.IA strains did not bind CFHR5 (Fig. S4 in Supplemental File 1). CFH similarly bound gonococcal PorB as CFH, although mutational analysis and examination of clinical isolates revealed that the precise sites of CFH and CFHR5 binding on P.IB differ subtly. Our results suggest that modification of L1 affects CFH binding more than CFHR5, while changes in L6 affect CFHR5 binding more than CFH.

Apart from PorB, we demonstrated that LPS sialylation was required for CFHR5 binding to both the meningococcus and gonococcus. It is unknown how LPS sialylation contributes to the recruitment of complement factors by pathogenic Neisseria. CFH recognizes negatively charged surfaces on host and pathogen membranes, such as glycosaminoglycans (reviewed in reference (6)). Therefore, the presence of the negatively charged sialic acid group to LPS might act cooperatively with PorB to form a docking site for complement factor binding or affect the conformation of the extracellular loops of PorB and indirectly facilitate CFH and CFHR5 binding.

The binding of CFHR5 to pathogenic Neisseria could influence complement regulation by CFH and result in the recruitment of other immunomodulatory molecules, such as properdin and pentraxins (10). Accumulation of properdin could contribute to complement activation at the site of infection, enhancing complement activity on the bacterial surface as properdin is a positive regulator of the AP (10), provoking local proinflammatory responses. Indeed, low CFHR5 levels in an individual with a CFHR5 frameshift mutation were associated with renal disease development after Streptococcus pneumoniae infection (49). Our data support this hypothesis as the addition of CFHR5 to sialylated N. gonorrhoeae enhanced the complement-mediated lysis of bacteria (Fig. 7A and B). CFHR5 had no detectable effect when added to unsialylated N. gonorrhoeae, consistent with the finding that the addition of sialic acid to LPS is crucial for complement evasion (50). This is consistent with CFHR5 modulating complement activation, probably by competing with CFH for binding to PorB (Fig. 7C), in a manner analogous to the competition between CFHR3 and CFH for meningococcal fHbp (17). It is likely that bacteria evolved to recruit CFH but may be unable to distinguish the negative complement regulator from the CFHRs due to their high structural and sequence identity. The outcome of binding on complement activation will be determined by the local levels of CFHR5 and CFH along with their relative affinities for their bacterial target. Of note, high CFHR5 levels have been observed in otitis media with effusion which was hypothesized to compete with CFH for binding of C3b enabling rapid enhancement of complement activation (51). Furthermore, fine-tuning complement activation at the site of infection could be achieved by the therapeutic use of CFHRs to combat infectious diseases. Increasing CFHR levels could result in enhanced AP activation and clearance of bacteria by the immune system.

In summary, we have characterized specific MAbs for detecting CFHR2, 4, and 5, which will help in understanding the function of the CFHRs and their interactions with microbes. Using these MAbs, we demonstrated that CFHR5 was bound to the surface of pathogenic Neisseria spp. when LPS was sialylated. While N. meningitidis and N. gonorrhoeae employed distinct strategies to recruit CFH, there were remarkable parallels between the mechanisms of CFHR5 recruitment by these pathogens, where both pathogens bind CFHR5 via PorB in the presence of sialylation. Specific PorB loops are involved in CFHR5 binding in N. gonorrhoeae, which antagonized the effect of CFH on bacterial survival in the presence of human complement, highlighting the complex interactions between pathogenic Neisseria spp. and human complement.
TABLE 2 Antibodies

| Antibody target | Antibody name   | mAb/pAb | Isotype | Reference/supplier |
|-----------------|-----------------|---------|---------|--------------------|
| CFH             | OX-24           | mAb     | IgG1    | 29                 |
| CFHR2           | HSL-2           | mAb     | IgG1    | This study         |
| CFHR3           | HSL-1           | mAb     | IgG1    | 17                 |
| CFHR4           | HSL-4           | mAb     | IgM     | This study         |
| CFHR5           | HSL-5           | mAb     | IgG1    | This study         |
| PorA            | Anti-meningococcal serotype P1.7 | mAb    | IgG2a   | NIBSC, UK (63)     |
| PorB            | Anti-meningococcal serotype P3.15 | mAb    | IgG2a   | NIBSC, UK (63)     |
| PorB P.IB       | H5.2            | mAb     | IgG2a   | 64                 |
| Lst             | Anti-Lst        | pAb     |         | 65                 |
| Mouse IgG       | Goat anti-mouse immunoglobulins/HRP | pAb    |         | Agilent, Dako      |
| Mouse IgG       | Goat anti-mouse IgG (H + L) Alexa Fluor 647 | pAb    |         | LifeTech, ThermoFisher Scientific |
| Mouse IgM       | Goat anti-mouse IgG (H + L) Alexa Fluor 488 | pAb    |         | LifeTech, ThermoFisher Scientific |

MATERIALS AND METHODS

Bacterial strains and growth. Bacterial strains used in this study are listed in Table 1. N. meningitidis were grown on brain heart infusion (BHI) agar (1.5% [wt/vol], Oxoid) supplemented with 5% Levinthal's base (500 mL defibrinated horse blood autoclaved with 1 L BHI). N. gonorrhoeae was grown in a gonococcal base liquid medium (GCBL) consisting of 1.5% (wt/vol) proteose peptone number 3 (Becton, Dickinson), 0.1% (wt/vol) starch, 0.4% (wt/vol) K2HPO4, 0.1% (wt/vol) KH2PO4, 0.5% (wt/vol) NaCl supplemented with 1% Vitox (Oxoid). Agar 1.5% (wt/vol) (Oxoid) was included for solid medium. Cultures were then incubated for 16 to 18 h at 37°C with 5% CO2. Escherichia coli was grown on Luria-Bertani agar (Oxoid) overnight at 37°C. For growth assays, measurements of the Optical Density (A600) were taken every hour for 4 h. N. gonorrhoeae was sialylated by the addition of 2 μg mL⁻¹ of cytidine-5'-monophospho-N-acetyleneuraminic acid (CMP-NANA) to media. For Neisseria spp., kanamycin (kan) and erythromycin were added to media at 50 μg mL⁻¹ and 2 μg mL⁻¹, respectively. Ampicillin (100 μg mL⁻¹) was used for Escherichia coli as required.

Generation of bacterial strains. N. meningitidis H44/76ΔporB was generated by insertional inactivation of porB with a cassette encoding kan resistance. Primer pairs porB forward/porB reverse (Table S1 in Supplemental File 1 shows all primers), along with porB forward/porB reverse were designed to amplify porB and introduce a Sall restriction site within the open reading frame. PCR products were joined by overlap PCR using primers porB forward/porB reverse and then introduced into pGEM-T Easy (Promega). Constructs were verified by sequencing. Kan resistance cassette was amplified using overlap primers porB forward/porB reverse with Sall recognition sites at the 5' ends and ligated into the Sall site in porB in pGEM-T Easy. The porB::kan construct was amplified by PCR using primers porB forward/porB reverse. Plasmids for modifying gonococcal PorB loops were kindly provided by Hank Seifert (26). Plasmids were purified by GenElute (Sigma) according to the manufacturer’s instructions. Linearized plasmid DNA or amplified constructs were used to transform Neisseria (22). Transformants were identified by plating to selective media and verified by PCR and sequencing.

Generation of anti-CFHR MAbs. All work with animals was conducted in accordance with the United Kingdom Home Office guidelines under relevant project licenses. Expression and purification of CFH13,20, CFHR1,4,5, CFHR2,3,4, CFHR3,4,5, CFHR4,8, and CFHR5,9 were described previously (7, 17). MAbs were raised against recombinant CFHR2,4, CFHRS1,9, and a linear peptide of CFHR4 (ENSRAKSNGM, Severn Biotech Ltd., UK) conjugated to keyhole limpet hemocyanin (Imject mcKLH, Pierce) as antigens to immunize female BALB/c mice (Charles Rivers, Margate) as previously described (17). ELISA plates (F96 maxisorp, Nunc) were coated with unconjugated CFH13,20, CFHR1,4,5, CFHR2,3,4, CFHR3,4,5, CFHR4,8, or CFHRS1,9 (5 μg mL⁻¹, 50 μL per well) or the linear peptide of CFHR4 and screening was performed as previously described (17). MAbs used in this study are listed in Table 2.

Supernatants from hybridomas grown in Gibco Protein Free Hybridoma Medium II (PFHM II) were diluted 1:1 with 50 mM sodium acetate, pH 5.0. Protein G chromatography cartridges (Pierce, ThermoFisher Scientific) were used to purify MAbs and eluted with Pierce IgG elution buffer (ThermoFisher Scientific) and quantified using a Nanodrop 2000c spectrophotometer (ThermoFisher Scientific). MAbs were isotyped using a Mouse Monoclonal Antibody Isotyping Test kit (Bio-Rad, UK).

SDS-PAGE and Western blotting. To examine MAb specificity, 1% normal human serum (NHS, vol/vol) was used as samples as previously described (22). PorB was detected as described previously (22), using anti-PorB MAb H5.2 (29). Protein was transferred to nitrocellulose membrane (Amersham) and detected using Goat anti-mouse HRP (Dako) (52). Coomassie brilliant blue staining was used to visualize proteins.

Flow cytometry. Flow cytometry for N. gonorrhoeae was performed as previously (26). For N. meningitidis the protocol had the following exceptions. Antibody incubations were for 1 h, and PBS 0.05% BSA (wt/vol) was the wash buffer. Recombinant CFHRs (R&D) and purified CFH (Sigma-Aldrich) were also used to detect binding. Anti-CFHR MAb supernatants, purified OX-24 (10 μg mL⁻¹), or purified HSL-5 (1 μg mL⁻¹) were used as primary antibodies. anti-P1.7 and anti-P3.15 MAbs (NIBSC, UK) were used to quantify meningococcal PorA and PorB expression, respectively, while N. gonorrhoeae PorB was detected with MAb H5.2. Goat anti-mouse IgG-Alexa fluor 647 or goat anti-mouse IgM Alexa Fluor 488-conjugated (both Molecular Probes, Life Technologies) pAbs were used as secondary antibodies. Results were...
expressed as the geometric mean fluorescence (GMB, FlowJo vX software, Tree Star). Statistical significance was tested using an unpaired Student’s t test or one-way ANOVA, as indicated (GraphPad Prism v6.0). Serum survival assay. N. gonorrhoeae was grown in GCBL with or without CMP-NANA from overnight growth on GCB agar. A total of 5 × 10^5 CFU of bacteria diluted in Eagle’s minimum essential medium (EMEM) (Sigma) were preincubated with 4 μM CFHRS or PBS for 15 min before incubation with 75% IgG and IgM depleted, human complement (HComplement) (of Pel-Freez LLC, USA) or heat-inactivated HComplement (Hi-HComplement) for 45 min at 37°C in the presence of CO2. Bacterial survival was determined by plating onto GCB agar. Relative survival was calculated from samples containing no CFHRS and incubated with Hi-HComplement expressed as percentage survival. Statistical significance was tested using the two-way ANOVA multiple comparisons in GraphPad Prism v.9.0 (GraphPad Software Inc.) to compare means ± S.D. using a P < 0.05 cutoff for significance.

SUPPLEMENTAL MATERIAL
Supplemental material is available online only.

SUPPLEMENTAL FILE 1
PDF file, 0.3 MB.

ACKNOWLEDGMENTS
The authors do not report a conflict of interest related to the manuscript.

This work was supported by the Wellcome Trust (awards 102908/Z/13/Z and 221924/Z/20/Z to C.M.T.), the Guy Newton Research Fund Translational Grant (HL), and an A*STAR scholarship (W.Y.Y.).

REFERENCES
1. Ricklin D, Hajishengallis G, Yang K, Lambris JD. 2010. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: 785–797. https://doi.org/10.1038/ni.1923.
2. Zipfel PF, Hallström T, Riebesck K. 2013. Human complement control and complement evasion by pathogenic microbes - Tipping the balance. Mol Immunol 56:152–160. https://doi.org/10.1016/j.molimm.2013.05.022.
3. Józsi M, Zipfel PF. 2008. Factor H family proteins and human diseases. Trends Immunol 29:380–387. https://doi.org/10.1016/j.it.2008.04.008.
4. Ripoche J, Day AJ, Harris TJ, Sim RB. 1988. The complete amino acid sequence of human complement factor H. Biochem J 29:593–602. https://doi.org/10.1042/bj2409593.
5. Kristensen T, Tack BF. 1986. Murine protein H is comprised of 20 repeating units, 61 amino acids in length. Proc Natl Acad Sci U S A 83:3963–3967. https://doi.org/10.1073/pnas.83.11.3963.
6. Rodríguez De Córdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P. 2004. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 41:355–367. https://doi.org/10.1016/j.molimm.2004.02.005.
7. Goicoechea de Jorge E, Caesar JE, Mallik HK, Patel M, Colledge M, Johnson S, Hakobyan S, Morgan BP, Harris CL, Pickering MC, Lea SM. 2013. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci U S A 110:4685–4690. https://doi.org/10.1073/pnas.1219260110.
8. Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT. 2013. Complement factor H related proteins (CFHRs). Mol Immunol 56:170–180. https://doi.org/10.1016/j.molimm.2013.06.001.
9. Zipfel PF, Wiech T, Stea ED, Skerka C. 2020. CFHR gene variations provide insights in the pathogenesis of the kidney diseases atypical hemolytic uremic syndrome and C3 glomerulopathy. J Am Soc Nephrol 31:241–256. https://doi.org/10.1681/ASN.2019050515.
10. Cisnci ÆI, Kopp A, Žoldi M, Bánáki Z, Uzonyi B, Hebecker M, Caesar JJE, Pickering MC, Daigo K, Hamakubo T, Lea SM, Goicoechea de Jorge E, Józsi M. 2015. Factor H–related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation. J Immunol 194:4963–4973. https://doi.org/10.4049/jimmunol.1403121.
11. Chen Q, Manzke M, Hartmann A, Buttner M, Amann K, Pauly D, Wiesener M, Skerka C, Zipfel PF, Böttner M, Amann K, Pauly D, Wiesener M, Skerka C, Zipfel PF. 2016. Complement factor H–related S-hybrid proteins anchor properdin and activate complement at self-surfaces. J Am Soc Nephrol 27:1413–1423. https://doi.org/10.1681/ASN.2015020212.
12. Ferreira VP, Pangburn MK, Cortes C. 2010. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol 47: 2187–2197. https://doi.org/10.1016/j.molimm.2010.05.007.
13. Siegel C, Hallström T, Skerka C, Eberhardt H, Uzonyi B, Beckhaus T, Karas M, Wallich R, Stevenson B, Zipfel PF, Kraiczky P. 2010. Complement factor H-related proteins CFHR2 and CFHRS represent novel ligands for the infection-associated CRASP proteins of Borelia burgdorferi. PLoS One 5: e13519. https://doi.org/10.1371/journal.pone.0013519.
14. Hauk T, Reuter M, Van Den Elsen J, Burman J, Hálíček S, Richter J, Skerka C, Zipfel PF. 2008. The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement factor H and C3b. PLoS Pathog 4:e1000250. https://doi.org/10.1371/journal.ppat.1000250.
15. Kunert A, Losse J, Gruszin C, Hünn M, Kaendler K, Mikkat S, Volke D, Hoffmann R, Jokiranta TS, Seebeger H, Moellmann U, Hellwage J, Zipfel PF. 2007. Immune evasion of the human pathogen Pseudomonas aeruginosa: elongation factor Tuf is a factor H and plasminogen binding protein. J Immunol 179:2979–2988. https://doi.org/10.4049/jimmunol.179.5.2979.
16. Agarwal S, Ram S, Ngampasutadol J, Gulati S, Zipfel PF, Rice PA. 2010. Factor H facilitates adherence of Neisseria gonorrhoeae to complement receptor 3 on eukaryotic cells. J Immunol 185:4344–4353. https://doi.org/10.4049/jimmunol.0904191.
17. Caesar JJE, Lavender H, Ward PN, Exley RM, Eaton J, Chittock E, Malik TH, Goicoechea de Jorge E, Pickering MC, Tang CM, Lea SM. 2014. Competition between antagonistic complement factors for a single protein on N. meningitidis rules disease susceptibility. Elife 3:e04008. https://doi.org/10.7554/elif.04008.
18. Elias J, Frosch M, Vogel U. 2015. Neisseria, p 635–651. In Manual of Clinical Microbiology. John Wiley & Sons, Ltd.
19. Schneider MC, Exley RM, Chan H, Feavers I, Kang Y-H, Sim RB, Tang CM. 2006. Functional significance of factor H binding to Neisseria meningitidis. J Infect 176:7566–7575. https://doi.org/10.1016/j.jinf.2013.12.7566.
20. Giuntini S, Pajon R, Ram S, Granoff DM. 2015. Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity. Infect Immun 83:1536–1545. https://doi.org/10.1128/IAI.02984-14.
21. Lewis LA, Vu DM, Vasudheva S, Shaughnessy J, Granoff DM, Ram S. 2013. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. mBio 4:e00339-13–e00313. https://doi.org/10.1128/mBio.00339-13.
22. Jongerius I, Lavender H, Tan L, Ruivo N, Exley RM, Caesar JJE, Lea SM, Johnson S, Tang CM. 2013. Distinct binding and immunomucous properties of the gonococcal homologue of meningococcal factor H binding protein. PLoS Pathog 9:e1003528. https://doi.org/10.1371/journal.ppat.1003528.
23. Ngampasutadol J, Ram S, Gulati S, Agarwal S, Li C, Visintin A, Monks B, Madico G, Rice PA. 2008. Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J Immunol 180:3426–3433. https://doi.org/10.4049/jimmunol.180.5.3426.
24. Carbonetti NH, Simnad VI, Seifert HS, So M, Sparling PF. 1988. Genetics of protein I of Neisseria gonorrhoeae: construction of hybrid porins. Proc Natl Acad Sci U S A 85:6841–6845. https://doi.org/10.1073/pnas.85.18.6841.
virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol 18:1002–1014. https://doi.org/10.1128/CVI.00055-11.
61. Seifert HS, Wright CJ, Jerse AE, Cohen MS, Cannon JG. 1994. Multiple gonococcal pilin antigenic variants are produced during experimental human infections. J Clin Invest 93:2744–2749. https://doi.org/10.1172/JCI117290.
62. Cehovin A, Harrison OB, Lewis SB, Ward PN, Ngetsa C, Graham SM, Sanders EJ, Maiden MCJ, Tang CM. 2018. Identification of novel Neisseria gonorrhoeae lineages harboring resistance plasmids in coastal Kenya. J Infect Dis 218:801–808. https://doi.org/10.1093/infdis/jiy240.
63. Poolman JT, Kriz-Kuzemenska P, Ashton F, Bibb W, Dankert J, Demina A, Frøholm LO, Hassan-King M, Jones DM, Lind I, Prakash K, Xujing AH. 1995. Serotypes and subtypes of Neisseria meningitidis: results of an international study comparing sensitivities and specificities of monoclonal antibodies. Clin Diagn Lab Immunol 2:69–72. https://doi.org/10.1128/cdli.2.1.69-72.1995.
64. Nachamkin I, Cannon JG, Mittler RS. 1981. Monoclonal antibodies against Neisseria gonorrhoeae: production of antibodies directed against a strain-specific cell surface antigen. Infect Immun 32:641–648. https://doi.org/10.1128/iai.32.2.641-648.1981.
65. Shell DM, Chiles L, Judd RC, Seal S, Rest RF. 2002. The Neisseria lipooligosaccharide-specific alpha-2,3-sialyltransferase is a surface-exposed outer membrane protein. Infect Immun 70:3744–3751. https://doi.org/10.1128/IAI.70.7.3744-3751.2002.